2022-10-20 01:38:09
Recently, the National Intellectual Property Administration released the list of "2022 National Intellectual Property Advantage Demonstration Enterprises". HFCIM has been honored as the "National Intellectual Property Advantage Enterprise" for the year 2022. This recognition comes as a result of the HFCIM's outstanding performance in intellectual property. Following the success in winning gold and silver at the 2021 China Patent Award, this new national-level honor signifies a further advancement in HFCIM's comprehensive capabilities in intellectual property creation and management.
"National Intellectual Property Advantage Enterprise" refers to enterprises that belong to key development industries at the national and municipal levels. These enterprises are capable of undertaking significant and key projects in national and local industrial development and possess independent intellectual property capabilities, actively engage in intellectual property protection and utilization, establish comprehensive intellectual property management systems and mechanisms, and demonstrate overall strength in intellectual property.
Since its establishment, HFCIM has adhered to the principle of "driving the continuous development of the company with intellectual property." HFCIM has conducted a full-chain approach to intellectual property creation, protection, utilization, and management. As of now, HFCIM has applied for nearly 400 patents and has been granted over 200 patents. In addressing common technologies within the industry, HFCIM has refined advanced standards, leading the development of one international standard, two national standards, 25 provincial local standards, and over 20 other standards.
The honor is an affirmation and support from various levels of regulatory authorities for HFCIM's technological innovation and intellectual property efforts. In the future, HFCIM will continue to increase R&D investment, develop homemade proton therapy systems, establish an international leading research and manufacturing center for nuclear medicine equipment.